Peregrine Pharma (PPHM) Reports In-Line Q3 Loss of 13c/Share

Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM) reported Q3 EPS of ($0.13), in-line with the analyst estimate of ($0.13). Revenue for the quarter came in at $3.28 million versus the consensus estimate of $2.12 million.

For earnings history and earnings-related data on Peregrine Pharmaceuticals, Inc. (PPHM) click here.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Blackhawk Network (HAWK) Reports Q2 Loss of $0.07; Offers Guidance
• Cineverse Corp (CNVS) Misses Q1 EPS by 20c; Offers Guidance
• 4D Molecular Therapeutics, Inc. (FDMT) Misses Q2 EPS by 3c